Table 1.
Prediction accuracies of ADC-SCC and Tumor-Nonmalignant Signatures
| Signature Type | Dataset | Expression Platform | Training or Testing | Sensitivity | Specificity | Accuracy |
|---|---|---|---|---|---|---|
| ADC-SCC | SPORE/MDACCa | Illumina WG-6 V3 | Training | 170/183 (93%)c | 72/80 (90%)d | 242/263 (92%) |
| ADC-SCC | SPORE/MDACCb | Illumina WG-6 V3 | Training | 170/178 (96%) | 78/83 (94%) | 248/261 (95%) |
| ADC-SCC | TCGAa | RNAseq | Testing | 475/490 (97%) | 456/489 (93%) | 931/979 (95%) |
| ADC-SCC | TCGAb | RNAseq | Testing | 423/437 (97%) | 437/453 (96%) | 860/890 (97%) |
| ADC-SCC | EDRN/Canary | Illumina WG-6 V3 | Testing | 82/83 (99%) | NA | 82/83 (99%) |
|
| ||||||
| Tumor-Nonmalignant | EDRN/Canary | Illumina WG-6 V3 | Training | 83/83 (100%)e | 83/83 (100%)f | 166/166 (100%) |
| Tumor-Nonmalignant | TCGA | RNAseq | Testing | 959/979 (98%) | 108/108 (100%) | 1067/1087 (98%) |
| Tumor-Nonmalignant | SPORE/MDACC | Illumina WG-6 V3 | Testing | 252/275 (92%) | NA | 252/275 (92%) |
|
| ||||||
| ADC-SCC | FFPE Resected | HTG EdgeSeq | Testing | 16/17 (94%) | 18/18 (100%) | 34/35 (97%) |
| ADC-SCC | FFPE CNB | HTG EdgeSeq | Testing | 15/19 (79%) | 17/17 (100%) | 32/36 (89%) |
| Tumor-Nonmalignant | FFPE Resected | HTG EdgeSeq | Testing | 33/35 (94%) | 11/11 (100%) | 44/46 (96%) |
| Tumor-Nonmalignant | FFPE CNB | HTG EdgeSeq | Testing | 35/36 (97%) | NA | 35/36 (97%) |
a
Original histopathological diagnosis
b
Revised histopathological diagnosis
c
Predicted ADC (score > 0)/Diagnostic ADC
d
Predicted SCC (score < 0)/Diagnostic SCC
e
Predicted Tumor (score > 0)/Diagnostic Tumor
f
Predicted Non-Malignant (score < 0)/Diagnostic Non-Malignant
Abbreviations: FFPE, Formalin-Fixed Paraffin-Embedded; CNB, Core Needle Biopsy